Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
Lj6w3zSDuDxGhHK2
